How Competitors Influence Strategic Factor Market Decisions
New research reveals how firms respond to rivals' moves in resource allocation
1Competition Dynamics in Factor Markets
While companies closely monitor competitors' activities in product markets, they often overlook movements in factor markets. Yet rivals' actions provide critical intelligence for resource allocation decisions. Research on global biopharmaceutical firms (1993-2018) shows 68% of companies react to competitors' factor market moves. This response rate is particularly high in R&D-intensive sectors where resource scarcity prevails.
2Three Strategic Response Patterns
The study identifies three distinct response mechanisms to competitors' factor market actions: herding behavior, strategic differentiation, and capability building. Herding is 42% more prevalent in information-asymmetric markets. In biotechnology, competitors' R&D investments trigger similar resource acquisitions by other firms. The response type depends on market transparency and firm-specific factors like absorptive capacity.
3The Dual Nature of Competitive Signals
Competitors' moves simultaneously provide information signals and create competitive pressure. Firm size mediates responses: 73% of large firms interpret rivals' actions as signals for internal development, while 61% of SMEs directly acquire resources from factor markets. This divergence stems from differences in resource access and organizational slack. The study quantifies these patterns across 450+ biopharma strategic initiatives.
4A New Resource Selection Framework
The research proposes a decision model for optimal resource picking in factor markets. It accounts for interaction effects between competitor density (89% impact in high-uncertainty markets), resource scarcity, and firm capabilities. For rare biological materials, competitor signals become 3.2x more influential. The model successfully predicts 78% of observed resource allocation patterns in validation tests.
5Biopharmaceutical Sector Evidence
Longitudinal data reveals competitors' clinical trial decisions influence 54% of firms' research orientations in drug development. An oncology-focused investment by one firm increases rivals' resource commitment to the same area by 2.3x. This herding effect is strongest (p<0.01) in early-stage drug discovery, where uncertainty peaks and information scarcity prevails across the innovation pipeline.
6Endogenous Capability Development
Some firms counterintuitively choose internal capability building despite competitive pressure. This strategy dominates in patent-protected (81% prevalence) and R&D-intensive (67%+) subsectors. For instance, 76% of mRNA technology developers pursued specialized capability paths independent of competitor moves. The study identifies three moderating factors enabling this counter-herding behavior.
7Market Condition Moderators
Factor market liquidity and transparency significantly shape competitive responses. Sensitivity to rival signals reaches 92% in illiquid markets (e.g., biological materials) versus 34% in liquid ones. Regulatory intensity also mediates responses—every additional regulation increases capability-building choices by 19%. These findings hold across multiple therapeutic areas and development stages.
8Shifting Competitive Strategy Paradigms
The study challenges traditional competitive analysis by demonstrating factor market interactions' strategic importance. In high-risk sectors like biopharma, correctly interpreting rivals' resource allocation decisions provides measurable advantage. The framework offers predictive power for strategic factor selection, with implications extending to other innovation-driven industries undergoing digital transformation.
Original article: Journal of Management Studies — Rakiplerin Faktör Piyasalarındaki Stratejik Etkisi